BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the Company's DPX™ formulations.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fifth tranche (the "Fifth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 4,500,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $225,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purchas